Rubius Therapeutics posts $47M loss in Q3 on increase in R&D expenses

CAMBRIDGE, Mass. - Rubius Therapeutics Inc. reported a loss of $47 million in the third quarter, or 59 cents per diluted share, the company announced on Thursday. The clinical-stage biopharmaceutical company reported a loss of $26.4 million in the third quarter of 2018, or 42 cents per diluted share.   The company has a 135,000-square-foot…

Want More?

Subscribe or register with Providence Business News to keep reading.

REGISTER
for 2 more stories

Subscribe now for $1 for 4 weeks
Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -